Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Albuterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 9/20 | 0.82 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.82 |
| ▸ | TSHR | P16473 | 2/20 | 0.82 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.81 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | THPO | P40225 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levosalbutamol SCHEMBL31301062 | 1.00 | ADRB2 (0.82) | ADRB2ADRB1CYP1A2TSHRNFKB1 | |
| Levosalbutamol SCHEMBL29394399 | 1.00 | ADRB2 (0.82) | ADRB2ADRB1CYP1A2TSHRNFKB1 | |
| Levosalbutamol SCHEMBL1247104 | 1.00 | ADRB2 (0.82) | ADRB2ADRB1CYP1A2TSHRNFKB1 | |
| Albuterol SCHEMBL6838948 | 0.92 | ADRB2 (0.87) | ADRB2ADRB1CYP1A2TSHRNFKB1 | |
| Albuterol SCHEMBL122805 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2TSHRNFKB1 | |
| Albuterol SCHEMBL2489838 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2TSHRNFKB1 | |
| Levosalbutamol SCHEMBL4003 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2TSHRNFKB1 | |
| Albuterol SCHEMBL4913 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2TSHRNFKB1 | |
| Albuterol SCHEMBL121596 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2TSHRNFKB1 | |
| (S)-Albuterol SCHEMBL29496690 | 0.91 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117919258-A | Medicinal liquid for treating bronchial asthma and administration device thereof | 周子栋 | 2024-04-26 | — | — | CN | claimed |
| CN-116392460-A | Salbutamol aerosol | 山东京卫制药有限公司 | 2023-07-07 | — | — | CN | claimed |
| CN-115463117-A | Budesonide salbutamol compound aerosol inhalation suspension with high delivery efficiency and preparation method thereof | 四川普锐特药业有限公司 | 2022-12-13 | — | — | CN | claimed |
| EP-2018162-A2 | METHODS FOR THE DELIVERY OF A BETA2 AGONIST TO INDUCE BRONCHODILATION AND FORMULATIONS FOR USE IN THE SAME | Tika Läkemedel AB (SE) | 2009-01-28 | — | — | EP | claimed |
| US-20080020003-A1 | Methods for the delivery of a beta2 agonist to induce bronchodilation and formulations for use in the same | VERUS PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | claimed |
| WO-2007137204-A2 | METHODS FOR THE DELIVERY OF A BETA2 AGONIST TO INDUCE BRONCHODILATION AND FORMULATIONS FOR USE IN THE SAME | TIKA LÄKEMEDEL AB (SE) | 2007-11-29 | — | — | WO | claimed |
| CN-1206205-C | Process for preparing R-salbutamol tartrate | CHENGDU ORGANIC CHEM INST (CN) | 2005-06-15 | — | — | CN | claimed |
| CN-1382685-A | Process for preparing R-salbutamol tartrate | CHENGDU ORGANIC CHEM INST (CN) | 2002-12-04 | — | — | CN | claimed |
| CN-117919258-A | Medicinal liquid for treating bronchial asthma and administration device thereof | 周子栋 | 2024-04-26 | — | — | CN | disclosed |
| CN-116392460-A | Salbutamol aerosol | 山东京卫制药有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-115463117-A | Budesonide salbutamol compound aerosol inhalation suspension with high delivery efficiency and preparation method thereof | 四川普锐特药业有限公司 | 2022-12-13 | — | — | CN | disclosed |
| US-20210290568-A1 | INHALABLE FORMULATION OF A SOLUTION CONTAINING LEVALBUTEROL TARTRATE | Huang, Cai Gu (US) | 2021-09-23 | — | — | US | disclosed |
| WO-2021188809-A1 | INHALABLE FORMULATION OF A SOLUTION CONTAINING LEVALBUTEROL TARTRATE | HUANG CAI GU (US) | 2021-09-23 | — | — | WO | disclosed |
| US-RE43984-E1 | Process for preparing isomers of salbutamol | CIPLA LIMITED (IN) | 2013-02-05 | — | — | US | disclosed |
| WO-2007137204-A2 | METHODS FOR THE DELIVERY OF A BETA2 AGONIST TO INDUCE BRONCHODILATION AND FORMULATIONS FOR USE IN THE SAME | TIKA LÄKEMEDEL AB (SE) | 2007-11-29 | — | — | WO | disclosed |
| US-6995286-B2 | Resolution of racemic mixture using tartaric acid | CIPLA LIMITED (IN) | 2006-02-07 | — | — | US | disclosed |
| EP-1349828-B1 | PROCESS FOR PREPARING ISOMERS OF SALBUTAMOL | CIPLA LTD (IN) | 2005-03-16 | — | — | EP | disclosed |
| US-20040054215-A1 | Process for preparing isomers of salbutamol | CIPLA LIMITED (IN) | 2004-03-18 | — | — | US | disclosed |
| EP-1349828-A1 | PROCESS FOR PREPARING ISOMERS OF SALBUTAMOL | Cipla Limited (IN) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002048090-A1 | PROCESS FOR PREPARING ISOMERS OF SALBUTAMOL | CIPLA LIMITED (IN) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054215-A1 | Process for preparing isomers of salbutamol | ADRB1, ADRB2, ADRB3 | ADRB2 2/4885ADRB1 1/4885CYP1A2 1134/4885 |
| US-20210290568-A1 | INHALABLE FORMULATION OF A SOLUTION CONTAINING LEVALBUTEROL TARTRATE | NDUFB5, PDE12, NDUFB7 | ADRB2 76/4885ADRB1 51/4885CYP1A2 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.